Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4

IntroductionCiltacabtagene autoleucel (cilta-cel) is a chimeric antigen receptor T-cell therapy approved for patients with relapsed/refractory multiple myeloma (RRMM). In the phase 3 trial, CARTITUDE-4 (NCT04181827), cilta-cel demonstrated improved efficacy vs. standard of care (SOC; daratumumab plu...

Descripció completa

Dades bibliogràfiques

Autors principals:	Doris K. Hansen, Xiaoxiao Lu, Omar Castaneda Puglianini, Sonja Sorensen, Saad Z. Usmani, Eileen Zhang, Stephen Huo, Yan Zhang, Zaina P. Qureshi, Sundar Jagannath
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2024-08-01
Col·lecció:	Frontiers in Immunology
Matèries:	multiple myeloma ciltacabtagene autoleucel CAR T therapy cost-per-responder analysis cost-effectiveness analysis daratumumab
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1408892/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!